Sulted in the control group and the Etoposide Topoisomerase inhibitor blood pressure gr He reduced pulse pressure to valsartan. Was in contrast to the results of studies with ACE inhibitors and dual neutral endopeptidase, no The Quincke in this study.54 These encouraging data reported ZCL 696 is now the most promising inhibitor and neutral endopeptidase dual AT1R ¬ in clinical trials to treat high blood pressure, such as the development of double-and AT1R antagonist neutral endopeptidase VNP 489 seems to be stopped. AT1R endothelin A and endothelin-receptor blockade is one of the most potent vasoconstrictor, and also an R The role in fibrogenesis, inflammatory ¬ information, oxidative stress, atherosclerosis, and the Hom salt homeostasis Of water, and pulmonary hypertension.55 57 Several endothelin receptor antagonists have been closed ¬ investigate the treatment of high blood pressure. The endothelin antagonist reached darusentan selective Ing Promised lowering blood pressure in patients with resistant hypertension ¬ important in the DAR-311 trial, 58 and gr Ere decrease in mean systolic and dia ¬ 24 h diastolic blood pressure than placebo or the symbol ¬antihypertensive agent guanfacine in the RAF patholytic 312 retention trial.59 than 61 are the negative effects of salt and water and the development of the peripheral border deme reps possibility of the endothelin A receptor and blockers58 probably the decision to discontinue development of darusentan on hold contributed. Nevertheless, these results raise the question whether AT1R and specificity of t of the dual endothelin A antagonists Reception ¬ effective and better tolerated gate As possible the specific endothelin A receptor blocker k Nnte. In a Phase IIb, randomized, double-blind, controlled EAA versus placebo controlled treatment trial andactive EAA in patients with stage 1 hypertension PS 433 540 in February reduced the systolic and diastolic ¬ nistes effective than placebo, with the h Chsten dose achieved a gr Ere reduction of AT1R blocker irbesartan ¬ Sartan. Furthermore, compared to all doses of irbesartan 433 540 hp with h Higher rates associated controlled The blood pressure at 12 weeks.62 Although these results were encouraging, but they were comparable Published in a peer-reviewed, and clinical development of this compound was subjected to a trading partner is found.63 endothelin and vasopeptidase inhibition is produced by the EEC Another metallopeptidase, the EEC. Dual-ECE and the neutral endopeptidase inhibitor reduces daglutril both proteinuria and glomerulosclerosis in rats with streptozotocin-induced diabetes in a Ausma compared with the ACE inhibitor captopril, 64 an effect not previously observed, although individual EEC inhibition.65 daglutril reduced pulmonary and right atrial pressure in patients with congestive heart failure, was 66 in this study in the year 2004 published and updated data of this substance are not available. However, some of the EEC and other dual inhibitors of neutral endopeptidase, such as SLV 338, in the pr Clinical Cladribine 4291-63-8 pipeline. Time lying down, spontaneously hypertensive rats was 338 SLV treatment well tolerated Is possible and fill with an improved survival rate and a significantly lower incidence of Schlaganf. However, the treatment had no significant effect on the combined therapy of blood pressure.67 Gegenw Ships is only one pharmacological agent is sufficient to achieve, is the adequacy.